<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590781</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb18087-02</org_study_id>
    <secondary_id>DUET 1-02</secondary_id>
    <nct_id>NCT04590781</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b/2 Multiple-Dose Study to Evaluate the Safety and Efficacy of XmAb18087 ± Pembrolizumab in Subjects With Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (DUET-1-02) Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to&#xD;
      assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab&#xD;
      in subjects with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after&#xD;
      locoregional therapy with surgery and/or radiation therapy, and XmAb18087 monotherapy in&#xD;
      subjects with extensive-stage small cell lung cancer (SCLC) that has progressed after&#xD;
      standard therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety), graded by CTCAE version 5.0</measure>
    <time_frame>42 Days</time_frame>
    <description>Determine the rates of treatment-emergent adverse events as graded by CTAE version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR, CR rate and PR rate as assessed by RECIST 1.1 criteria (efficacy)</measure>
    <time_frame>42 Days</time_frame>
    <description>Determine the overall response rate (ORR), complete response (CR) rate and partial response (PR) rate, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: XmAb18087 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, will enroll subjects with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: XmAb18087 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, will enroll subjects with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: XmAb18087 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C will enroll subjects with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb18087</intervention_name>
    <description>Monoclonal bispecific antibody</description>
    <arm_group_label>Part A: XmAb18087 Monotherapy</arm_group_label>
    <arm_group_label>Part C: XmAb18087 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XmAb18087 ± Pembrolizumab</intervention_name>
    <description>XmAb18087 ± Pembrolizumab</description>
    <arm_group_label>Part B: XmAb18087 + pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Adult subjects ≥ 18 years&#xD;
&#xD;
          -  Disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or&#xD;
             magnetic resonance imaging (MRI) scan&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  All subjects must have adequate archival tumor sample (slides or archival&#xD;
             formalin-fixed paraffin-embedded [FFPE] block[s] containing tumor that has not been&#xD;
             previously irradiated&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use a highly effective method&#xD;
             of birth control during and for 4 weeks after completion of study. success), or sexual&#xD;
             abstinence&#xD;
&#xD;
          -  Fertile male subjects must be willing to practice a highly effective method of birth&#xD;
             control for the duration of the study and continuing for 4 weeks after the last dose&#xD;
             of XmAb18087 or pembrolizumab (when applicable&#xD;
&#xD;
          -  Able and willing to complete the entire study according to the study schedule&#xD;
&#xD;
        Additional Inclusion Criteria for Part A and Part B Cohorts:&#xD;
&#xD;
        • Histologically or cytologically confirmed metastatic MCC or locoregional MCC that has&#xD;
        recurred following standard locoregional therapy with surgery and/or radiation therapy.&#xD;
&#xD;
        Additional Inclusion Criteria for Part A Cohorts:&#xD;
&#xD;
        • Subjects must have progressed on or been ineligible for treatment with anti-PD1 or&#xD;
        anti-PDL1 therapy.&#xD;
&#xD;
        Additional Inclusion Criteria for Part B Cohorts:&#xD;
&#xD;
        • Subjects must be eligible to receive pembrolizumab as standard of care.&#xD;
&#xD;
        Additional Inclusion Criteria for Part C Cohorts:&#xD;
&#xD;
        : Histologically or cytologically confirmed extensive-stage SCLC that has progressed&#xD;
        following standard therapies&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Additional Exclusion Criteria for Part B Cohorts: XmAb18087 in Combination with&#xD;
        Pembrolizumab In addition to the exclusion criteria in Section 8.6, subjects will be&#xD;
        excluded from Part B safety run-in and expansion cohorts administered XmAb18087 in&#xD;
        combination with pembrolizumab if they meet the following criteria:&#xD;
&#xD;
          -  Prior treatment with therapeutics directed at anti-programmed cell death 1 (anti-PD1)&#xD;
             or anti-programmed cell death ligand 1 (anti-PDL1)&#xD;
&#xD;
          -  Have severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Hickingbottom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Clinical Development, Xencor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zequn Tang, MD, PhD</last_name>
    <phone>858-480-3672</phone>
    <phone_ext>672</phone_ext>
    <email>ttang@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabrielle Golden</last_name>
    <phone>858-480-3121</phone>
    <phone_ext>221</phone_ext>
    <email>ggolden@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xin, MD</last_name>
      <phone>626-218-3582</phone>
      <email>yxing@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Doni Woo</last_name>
      <phone>626-218-3582</phone>
      <email>DWoo@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gino In, MD</last_name>
      <phone>323-865-3000</phone>
      <email>Gino.In@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carryl DuBois</last_name>
      <phone>323 865 3084</phone>
      <email>Carryl.DuBois@med.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra D'Angelo, MD</last_name>
      <phone>646-888-4159</phone>
      <email>dangelos@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Wheeler</last_name>
      <email>wheelers@mskcc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raid Aljumaily, MD</last_name>
      <phone>405-271-1632</phone>
      <email>Raid-Aljumaily@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Caldwell, LPN</last_name>
      <phone>405 271 8001</phone>
      <phone_ext>48171</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailender Bhatia, MD</last_name>
      <phone>206-606-6326</phone>
      <email>renmelpc@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>Sam Kiriuk</last_name>
      <phone>206-606-7341</phone>
      <email>smlim@seattlecca.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCC</keyword>
  <keyword>SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

